Aurobindo Q1 FY27: consolidated PAT +25% YoY to ₹1,032 Cr as margins near 21% target

Aurobindo Pharma's consolidated revenue came in at ₹9,150 Cr (+16.3% YoY, +3.4% QoQ) and PAT at ₹1,032 Cr (+25.2% YoY reported). Stripping out a ₹40.18 Cr one-off — acquisition and related costs for the Lannett Company LLC deal, booked as an exceptional item — adjusted PAT growth is closer to ~28.5% YoY, since the charge depressed rather than inflated the reported number. Standalone PAT of ₹737 Cr grew a faster 31.9% YoY; the ~6.6-point gap versus consolidated growth is explained by items that hit only the group numbers — the Lannett acquisition costs and a ₹43.26 Cr US lease-receivable derecognition loss at Aurobindo Pharma USA — so the two bases tell a similar underlying story despite the divergence.

Margins expanded on both counts: EBITDA (computed) of roughly ₹1,881 Cr implies a margin of ~20.6% of operating revenue, up from 19.8% in Q4 FY26 and 20.4% a year ago, while net margin rose to 11.3% from 10.3% both sequentially and annually. This tracks toward, but has not yet reached, management's stated goal from the Q4 FY26 call of sustaining and progressively improving EBITDA margin to over 21% in FY27.

The stock went into the print at ₹1,613.4, up 1.9% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

Against our pre-result preview, the print is a revenue beat: we had flagged an expected range of ₹8,200-8,500 Cr and an EBITDA margin of 20-21%; actual revenue landed well above that band while the margin printed inline within it. An independent brokerage consensus PAT figure for this specific quarter could not be confirmed via search. The broader Street stance captured in our preview was constructive but cautious — 21 of 27 covering analysts rate the stock Buy, yet the 12-month average target of ₹1,393.63 implies downside from the ₹1,580.2 pre-result price, suggesting near-term optimism was already priced in. Management's own prior guidance also pointed to US expansion toward a $2 billion sales target (aided by Lannett) and double-digit European growth; this filing discloses only a single reportable Pharmaceuticals segment with no geographic revenue break-up, so those specific targets cannot be independently verified from the numbers here, and no management press release was available to cross-check their own framing of the quarter.